Published in Anti-Infectives Week, February 20th, 2006
The marketing approval was granted in the 25 member states of the European Union, Iceland, Liechtenstein, and Norway. Under the approval, Cubicin is indicated for the treatment of complicated skin and soft-tissue infections caused by Gram-positive bacteria.
Cubicin is expected to become available in the United Kingdom and the Netherlands shortly, followed by additional European countries, in accordance with local legal regulations.
"The launch of Cubicin in Europe provides an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Anti-Infectives Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.